Phase 2Completed
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
An Open Label Trial of TMC114/Rtv in HIV-1 Infected Subjects Who Were Randomized in the Trials TMC114-C201, TMC114-C207 or in Sponsor Selected Phase I Trials
- Sponsor
- Tibotec Pharmaceuticals, Ireland (Industry)
- Enrollment
- 52 enrolled
- Conditions
- HIV
- Interventions
- TMC114; rtv
- Ages
- adults, older adults
- Registry
- NCT02187107
Full record on ClinicalTrials.gov
From the registry
The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants. In addition, antiviral activity and immunological effect were also evaluated.
Primary outcomes
- Number of participants with adverse events as a measure of safety and tolerability of TMC114/RTV 600/100 mg combination
History
Last registry update
Registered
Study completion
Primary completion
Started